Bristol-Myers Squibb Company Underwriting AgreementUnderwriting Agreement • November 27th, 2006 • Bristol Myers Squibb Co • Pharmaceutical preparations • New York
Bristol-Myers Squibb Company, a corporation organized under the laws of Delaware (the “Company”), proposes to sell to the several underwriters named in Schedule II hereto (the “Underwriters”), for whom you (the “Representatives”) are acting as representatives, the principal amount of its securities identified in Schedule I hereto (the “Securities”), to be issued under an indenture (the “Indenture”) dated as of June 1, 1993, between the Company and JPMorgan Chase Bank (formerly known as The Chase Manhattan Bank), as trustee (the “Trustee”). To the extent there are no additional Underwriters listed on Schedule II other than you, the term Representatives as used herein shall mean you, as Underwriters, and the terms Representatives and Underwriters shall mean either the singular or plural as the context requires. Certain terms used herein are defined in Section 24 hereof.
Bristol-Myers Squibb Company Subscription AgreementSubscription Agreement • November 27th, 2006 • Bristol Myers Squibb Co • Pharmaceutical preparations • New York
Bristol-Myers Squibb Company, a corporation organized under the laws of Delaware (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell to the Managers named in Schedule I hereto (the “Managers”), for whom you (the “Representatives”) are acting as representatives, an aggregate of €500,000,000 principal amount of its 4.375% Senior Notes due 2016 (the “2016 Notes”) and €500,000,000 principal amount of its 4.625% Senior Notes due 2021 (the “2021 Notes”, and together with the 2016 Notes, the “Securities”). The Securities will be offered and sold to the Managers without being registered under the United States Securities Act of 1933, as amended (the “Securities Act”), in reliance upon an exemption from the registration requirements thereof, and resold by the Managers outside the United States to non-U.S. persons in reliance on Regulation S under the Securities Act (“Regulation S”).
